 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12...4849505152535455565758...266267» |
- ||||| Opdivo (nivolumab) / Ono Pharma, BMS, Stivarga (regorafenib) / Bayer, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical: 🔥Regorafenib, Ipilimumab & Nivolumab for MSS #ColonCancer With Prior Chemotherapy @JAMAOnc https://t.co/a0iSil4rVm ✅🇺🇸Phs-I 39 pts 👉ORR 27.6%, mPFS 4 mo & mOS 20 mo ❌Responses limited to pts without liver mets 🧐Promising, at least... @myESMO @OncoAlert (Twitter) - Mar 9, 2023
- | CRS-207 / Novartis, Keytruda (pembrolizumab) / Merck (MSD), Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date, Metastases: Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer (clinicaltrials.gov) - Mar 9, 2023
P2, N=20, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- || Enrollment closed, Trial completion date: Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer (clinicaltrials.gov) - Mar 9, 2023
P2, N=61, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Completed --> Active, not recruiting | Trial completion date: Oct 2022 --> Aug 2023
- |||| Opdivo (nivolumab) / Ono Pharma, BMS, Stivarga (regorafenib) / Bayer, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical: A promising phase I data of regorafenib-nivolumab-ipilimumab combination for pts with MSS-mCRC. 🔴 ORR 27.6% 🔴mPFS:4 months 🔴mOS:20 months Waiting for the phase-II data... @pashtoonkasi @DFarberYoungCRC @OncoAlert https://t.co/BPtNrnwP6f (Twitter) - Mar 9, 2023
- ||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
It is interesting there are inherent differences between the melanoma & lung experiences (eg TkI v PD1 in melanoma). But the fundamental principles are v similar. For example, this trial in which pCR after neoadj ipi/nivo indicated lack of need for adj IO https://t.co/e46oIGTANO (Twitter) - Mar 9, 2023
- Cost-Effectiveness of Pembrolizumab + Axitinib Versus Nivolumab + Ipilimumab As First-Line Treatment of Advanced Renal Cell Carcinoma in the Private Healthcare System in Brazil () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_2059;
Completed --> Active, not recruiting | Trial completion date: Oct 2022 --> Aug 2023 Pembrolizumab+axitinib is likely cost-effective in comparison to nivolumab+ipilimumab for patients with intermediate/poor prognostic IMDC risk aRCC from a Brazilian Private Healthcare System perspective.
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
A Targeted Review of Cost-Effectiveness of First- or Second-Line Immune Checkpoint Inhibitors in the Treatment of Patients with Braf Wild-Type Advanced Melanoma in the United States () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_1582;
Our targeted review summarizes the cost-effectiveness of ICIs in advanced melanoma patients in the US, with 1L pembrolizumab followed by 2L ipilimumab being cost-effective. However, further research is warranted to demonstrate these pharmacoeconomic analyses and their role in guiding clinicians and policymakers to adopt these therapies in a timely manner.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Budget Impact Analysis of Nivolumab Plus Ipilimumab for the Management of Advanced Unresected Malignant Pleural Mesothelioma (MPM) () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_1519;
Treatment of MPM patients with nivolumab plus ipilimumab has a budget impact with a cumulative increase in cost of $9,257,242 over a time horizon of 5 years. This increase in cost is due to the higher PFS value for the nivolumab plus ipilimumab combination (7 months) compared to only 3 months for both of the comparators.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Exploring Hidden Survival Heterogeneity Among First-Line (1L) Intermediate/Poor (I/P)-Risk Advanced Renal Cell Carcinoma (ARCC) Patients Treated with Nivolumab Plus Ipilimumab (NIVO+IPI) Via Parametric Mixture Models (PMM) () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_1395;
This increase in cost is due to the higher PFS value for the nivolumab plus ipilimumab combination (7 months) compared to only 3 months for both of the comparators. PMMs may adequately capture the complex survival and hazard trends for 1L I/P-risk aRCC patients treated with NIVO+IPI by offering insights on potential survival heterogeneity without making clinically restrictive assumptions.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Application of Bayesian Multi-Parameter Evidence Synthesis to Achieve Clinical Plausibility of Lifetime Survival Extrapolations in First-Line Advanced Non-Small Cell Lung Cancer (aNSCLC) () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_924;
B-MPES models generate robust estimates of long-term OS for aNSCLC patients receiving NIVO+IPI, even with limited follow-up. SPMs perform reasonably well in anticipating OS observed with extended follow-up but generate unreliable estimates for long-term OS without post hoc adjustment.
- Opdivo (nivolumab) / Ono Pharma, BMS
Cost-Effectiveness of First-Line Nivolumab Combination Therapy Vs Chemotherapy Alone for Advanced or Metastatic Esophageal Squamous Cell Carcinoma () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_730;
SPMs perform reasonably well in anticipating OS observed with extended follow-up but generate unreliable estimates for long-term OS without post hoc adjustment. Nivolumab combination therapy showed higher effectiveness at significantly higher cost compared to chemotherapy alone and is unlikely to be cost-effective as a first-line therapy for patients with advanced or metastatic esophageal squamous cell carcinoma in the U.S.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Cost-Effectiveness of Nivolumab Plus Ipilimumab in Gastro-Oesophageal Cancer in Japan () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_593;
Applying the threshold of JPY15 million/QALY, NIV+IPI treatment was not cost-effective. Further research on utility weights in the Japanese population and more valid biomarkers is needed for more refined analysis.
- Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab (NIVO+IPI) Versus Pembrolizumab Plus Axitinib (PEM+AXI) for the First-Line Treatment of Intermediate- and Poor (I/P)-Risk Advanced Renal Cell Carcinoma Patients in Colombia () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_464;
OBJECTIVES: Immuno-oncology (IO) combination NIVO+IPI and IO+tyrosine kinase inhibitor combination (PEM+AXI) therapies have demonstrated significant clinical benefits over sunitinib in the first-line (1L) treatment of I/P-risk advanced renal cell carcinoma (aRCC). This analysis shows that NIVO+IPI is estimated to be a life-extending and potentially cost-saving 1L treatment option when compared with PEM+AXI for I/P risk aRCC patients in Colombia.
- Padcev (enfortumab vedotin) / Seagen, Astellas, Yervoy (ipilimumab) / Ono Pharma, BMS
Beyond Conventional Clinical Value: Estimating the Impact of Accelerated Approvals on Therapeutic Bridging between Innovative Therapies () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_414;
This analysis shows that NIVO+IPI is estimated to be a life-extending and potentially cost-saving 1L treatment option when compared with PEM+AXI for I/P risk aRCC patients in Colombia. We estimated the ROV attributable to the FDA accelerated approval (AA) pathway for checkpoint inhibitors (CPIs) following ipilimumab
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Identifying and Quantifying Elements of Value for Nivolumab and Ipilimumab in First-Line Non-Small Cell Lung Cancer () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_129;
We estimated the ROV attributable to the FDA accelerated approval (AA) pathway for checkpoint inhibitors (CPIs) following ipilimumab Including novel value elements in the cost-effectiveness analysis for N+I as first-line mNSCLC strategy was able to capture additional value beyond the traditional payer perspective.
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed: CheckMate 9N9: An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread (clinicaltrials.gov) - Mar 8, 2023
P1/2, N=232, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Including novel value elements in the cost-effectiveness analysis for N+I as first-line mNSCLC strategy was able to capture additional value beyond the traditional payer perspective. Recruiting --> Active, not recruiting
- | Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Checkpoint inhibition, Mismatch repair, PD(L)-1 Biomarker, IO biomarker: Expression of DNA mismatch repair proteins in melanoma patients treated with immune checkpoint inhibitors. (Pubmed Central) - Mar 7, 2023
Reduced MMR protein expression is observed in CM and might predict favorable BOR in patients treated with ICI, as was observed for other entities. However, these findings need to be substantiated in larger patient cohorts.
- ||| Journal, Adverse events: Immunotherapy in Hepatogastroenterology - update 2022: efficacy and immune-related adverse events (Pubmed Central) - Mar 7, 2023
Durvalumab and CTx achieved promising results in a recent Phase 3 study...Early high-dose use of steroids negatively affects patient outcome. New therapy strategies for irAE are currently tested, such as extracorporeal photopheresis, but larger prospective trials are lacking.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date: Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers (clinicaltrials.gov) - Mar 7, 2023
P2, N=45, Recruiting, Sponsor: Dana-Farber Cancer Institute
New therapy strategies for irAE are currently tested, such as extracorporeal photopheresis, but larger prospective trials are lacking. Trial primary completion date: Oct 2023 --> Oct 2024
- |||||| Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical, Metastases: Triplet therapy with cabozantinib, nivolumab, and ipilimumab as first-line treatment in patients with advanced #RenalCellCarcinoma. @DrChoueiri joins @CaPsurvivorship in discussing the #COSMIC313 study on UroToday > https://t.co/vbf0mJyYSM @DanaFarber (Twitter) - Mar 6, 2023
- | Keytruda (pembrolizumab) / Merck (MSD), Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma (clinicaltrials.gov) - Mar 6, 2023
P2, N=70, Active, not recruiting, Sponsor: University of Chicago
Trial primary completion date: Oct 2023 --> Oct 2024 Trial completion date: Jun 2022 --> Jun 2026 | Trial primary completion date: Aug 2020 --> Jun 2022
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Analysis of immune-related adverse events correlated with good prognosis in melanoma treatment and fluctuating blood factors () - Mar 4, 2023 - Abstract #ISID2023ISID_1403;
Although more research with a larger number of patients is necessary, IFN-? and CXCL9/10 may be factors involved in the mechanism of the correlation between irAEs and a favorable prognosis.
- |||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical: A tailored immunotherapy regimen using nivolumab (Opdivo) induction & "boosts" with nivolumab & high-dose ipilimumab (Yervoy) as second-line treatment for mUC was associated with higher response rates compared with historical controls, reported @grimm_mo. https://t.co/GT4TM70Fm1 (Twitter) - Mar 3, 2023
- | Jemperli (dostarlimab) / GSK, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Checkpoint inhibition, Microsatellite instability, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker: Neoadjuvant Immune Checkpoint Inhibitor Therapy for Patients With Microsatellite Instability-High Colorectal Cancer: Shedding Light on the Future. (Pubmed Central) - Mar 3, 2023
Although nonoperative management of patients with MMR-D/MSI-H rectal cancer with ICIs will potentially define our current therapeutic approach, therapeutic goals of neoadjuvant ICI therapy for patients with MMR-D/MSI-H colon cancer may differ given that nonoperative management has not been well established for colon cancer. Herein, we overview recent advancements in ICI-based therapies for patients with early-stage MMR-D/MSI-H colon and rectal cancer and elaborate on the future treatment paradigm of this unique subgroup of CRC.
- | Enrollment change: Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative (clinicaltrials.gov) - Mar 3, 2023
P2/3, N=427, Recruiting, Sponsor: National Cancer Institute (NCI)
Herein, we overview recent advancements in ICI-based therapies for patients with early-stage MMR-D/MSI-H colon and rectal cancer and elaborate on the future treatment paradigm of this unique subgroup of CRC. N=100 --> 427
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Checkpoint inhibition: Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade (clinicaltrials.gov) - Mar 3, 2023
P1, N=20, Active, not recruiting, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
N=100 --> 427 Recruiting --> Active, not recruiting
- | Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal: Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma. (Pubmed Central) - Mar 2, 2023
Single agent anti-PD-1 achieves 20-30% MPR, the combination of ipilimumab and nivolumab doubles the MPR rates to 50-60%...S1801 compared TLND, followed by 18 courses of adjuvant pembrolizumab, to three courses of neoadjuvant pembrolizumab, followed by surgery and 15 adjuvant doses...There is rapid, consistent, and accumulating evidence generated from all phase 1 and phase 2 trials, indicating clinical superiority of neoadjuvant immunotherapy over adjuvant systemic therapy for macroscopic stage III melanoma. Therefore, payers should consider neoadjuvant immunotherapy for reimbursement
- | Journal, Metastases: Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline. (Pubmed Central) - Mar 2, 2023
For HER2-positive patients with gastric or GEJ AC who have progressed after first-line therapy, trastuzumab deruxtecan is recommended. In all cases, participation in a clinical trial is recommended as it is the panel's expectation that targeted treatment options for gastroesophageal cancer will continue to evolve.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.
- | Trial completion date, Trial primary completion date, Adverse events, Checkpoint inhibition: Autoantibodies in Treatment With Immune Checkpoint Inhibitors (AUTENTIC) (clinicaltrials.gov) - Mar 2, 2023
P=N/A, N=221, Recruiting, Sponsor: Hospital Universitario Araba
In all cases, participation in a clinical trial is recommended as it is the panel's expectation that targeted treatment options for gastroesophageal cancer will continue to evolve.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines. Trial completion date: Mar 2023 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Oct 2023
- || Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, IO biomarker: SiCARIO: Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer (clinicaltrials.gov) - Mar 2, 2023
P1/2, N=25, Recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Trial completion date: Mar 2023 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Oct 2023 Not yet recruiting --> Recruiting
- ||| cisplatin/vinblastine/SHAO-FA (INT230-6) / Intensity Therap
Trial completion, Trial completion date, Trial primary completion date, Metastases: KEYNOTE-A10: A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 (clinicaltrials.gov) - Mar 2, 2023
P1/2, N=110, Completed, Sponsor: Intensity Therapeutics, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Oct 2023 --> Feb 2023 | Trial primary completion date: Jul 2022 --> Feb 2023
- ||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical: agree completely, many confounding factors possible but several other studies showing similar correlation. I cringe when my patients on ipi/nivo tell me they went to dentist and got augmentin, or went to urgent care and abx for post nasal drip 👃 (Twitter) - Mar 2, 2023
- ||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical, Surgery: For patients presenting with clinically palpable disease, yes. We’ll have Qs about Pembro vs Ipi-Nivo vs something else, and about what to do post-op if path shows pCR, or if you can do a targeted dissection to assess the “sentinel node”. But yes, surgery first is done (Twitter) - Mar 1, 2023
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Biomarker, Journal, PD(L)-1 Biomarker, FDG PET, Metastases: FDG PET/CT Prognostic Markers in Patients with Advanced Melanoma Treated with Ipilimumab and Nivolumab. (Pubmed Central) - Mar 1, 2023
Active, not recruiting --> Completed | Trial completion date: Oct 2023 --> Feb 2023 | Trial primary completion date: Jul 2022 --> Feb 2023 Conclusion Baseline fluorine 18 fluorodeoxyglucose PET/CT metabolic tumor volume was an independent prognostic marker in patients with advanced melanoma who received ipilimumab and nivolumab treatment.
- ||| Enrollment closed, Trial completion date, Trial primary completion date: RELATIVITY-048: An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread (clinicaltrials.gov) - Mar 1, 2023
P1/2, N=255, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Conclusion Baseline fluorine 18 fluorodeoxyglucose PET/CT metabolic tumor volume was an independent prognostic marker in patients with advanced melanoma who received ipilimumab and nivolumab treatment. Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Nov 2026 | Trial primary completion date: Jan 2023 --> Apr 2024
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion: eNERGY: Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients (clinicaltrials.gov) - Mar 1, 2023
P3, N=217, Completed, Sponsor: Rennes University Hospital
Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Nov 2026 | Trial primary completion date: Jan 2023 --> Apr 2024 Active, not recruiting --> Completed
- | Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Checkpoint inhibition, Metastases: Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission. (Pubmed Central) - Mar 1, 2023
The planned addition of other treatment modalities converted another 4 patients (40%) to a durable 2nd remission. This sequential approach merits further exploration in prospective clinical trials.
- ||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical: A little provocative, but I think US sites might “overuse” ipi/nivo… significantly more tox, and you can always escalate, especially in low volume disease… if I had a clinical stage III node, I would happily receive a clip, neoadj PD1, a limited res -> adj (Twitter) - Feb 28, 2023
- |||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical: PD1 only for 2-3 cycles neoadjuvant as the SWOG1801, if not responding potentially ipi/nivo. However, most patients have low tumor burden at start so you don’t want to wait too long with your resection if not responding (Twitter) - Feb 28, 2023
- || relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Right now @gmboland low-dose ipi+nivo, but nivo+relatlimab (anti-LAG3) is promising too #asochat (Twitter) - Feb 28, 2023
- |||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical, Metastases: @OlofssonBagge& @ny_lars started SCANDIUM-2 which randomized patients with liver metastatic melanoma to ipi-nivo either before or after IHP. Recruitment has finished and data is submitted to a conference as an abstract.-> https://t.co/endTtGche7 (Twitter) - Feb 28, 2023
- Patient Experience of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer (ePoster Station #18) - Feb 28, 2023 - Abstract #ONS2023ONS_299;
Discussion and Implications: While patients experience symptoms from ICPIs, they recognize the benefits of disease control and report fewer symptoms. More research is needed to quantify the experience of ICPI therapy so that patients
- ||||| BMS-986226 / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial termination, IO biomarker: A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 28, 2023
P1/2, N=80, Terminated, Sponsor: Bristol-Myers Squibb
Completed --> Terminated; Study CA021-002 was terminated because the Sponsor discontinued further development of BMS-986226 due to a change in business objectives. The decision for the study closure was not related to any safety concerns associated with BMS-986226.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Checkpoint inhibition: Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases. (Pubmed Central) - Feb 27, 2023
DRESS induced by ICI are rare and of moderate severity. A consensus for management is still pending.
- || Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly
Retrospective data, Review, Journal, Metastases: Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis. (Pubmed Central) - Feb 27, 2023
A consensus for management is still pending. Sintilimab
- | Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim, Keytruda (pembrolizumab) / Merck (MSD)
Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma. (Pubmed Central) - Feb 27, 2023
Immune checkpoint inhibitors, such as pembrolizumab and nivolumab, are monoclonal antibodies that block programmed cell death 1 (PD-1) expressed on activated CD8+ T cells and play a crucial role in the treatment of advanced melanoma...After the surgery and the failure of ipilimumab and IL-2, he started immunotherapy with pembrolizumab...Our patient's rapid response to risankizumab enabled us to continue immunotherapy with pembrolizumab. The recognition of cutaneous signs of toxicity related to such drugs for advanced melanoma is of primary importance to start the correct treatment and continue the immunotherapy when possible.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Metastases: Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations. (Pubmed Central) - Feb 27, 2023
These findings do not support a change in current utilization practices for IO/IO and TKI/IO treatment strategies for ccRCC. PATIENT SUMMARY: In cases of metastatic clear cell renal cell carcinoma, no significant difference was observed in progression-free survival after second line of therapy between patients receiving ipilimumab plus nivolumab and those receiving a combination of a tyrosine kinase inhibitor and an immune checkpoint inhibitor.
- || Review, Journal, Checkpoint inhibition: Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression-free survival based on reconstructed individual patient data. (Pubmed Central) - Feb 27, 2023
Based on indirect comparisons, the combination of pembrolizumab+ipilimumab showed a particularly high efficacy, and so deserves further investigation. While the effect of between-trial differences in inclusion criteria plays an important role, our results do not support the proposal of relatlimab+nivolumab as a new standard of care.
- || Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
In this cenario would you prefer ipi-nivo or pembrolizumab? The data presented in CheckMate-142 trial seems better in this cenario to me. (Twitter) - Feb 25, 2023
- ||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical: These patients should get ipi nivo upfront. (Twitter) - Feb 24, 2023